IPP Bureau
Advent International launches Cohance Lifesciences
By IPP Bureau - November 02, 2022
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Lonza and Singzyme to accelerate development of Bioconjugates
By IPP Bureau - November 01, 2022
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Biocon ranks No. 8 in ‘Global Top Employers’ by Science magazine
By IPP Bureau - November 01, 2022
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Piramal Enterprises appoints Gautam Doshi as Additional Director
By IPP Bureau - November 01, 2022
His experience covers a wide range of areas including advisory services in the field of accounting, taxation, corporate and commercial laws, and regulatory matters
Glenmark Pharmaceuticals launches Fingolimod Capsules in US
By IPP Bureau - November 01, 2022
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
NHA organises workshop to accelerate adoption of ABDM
By IPP Bureau - November 01, 2022
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
Prasad Raghava Menon appointed Additional Director of Neuland Laboratories
By IPP Bureau - November 01, 2022
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program
By IPP Bureau - November 01, 2022
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
Aptar Pharma completes Phase I global injectables expansion program
By IPP Bureau - November 01, 2022
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Alembic Pharma gets USFDA approval for Glycopyrrolate Injection USP
By IPP Bureau - November 01, 2022
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
By IPP Bureau - October 31, 2022
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
USFDA issues Form-483 for Lupin's Nagpur Unit-2
By IPP Bureau - October 31, 2022
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility
By IPP Bureau - October 31, 2022
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Zydus receives final approval from USFDA for Acetaminophen injection
By IPP Bureau - October 30, 2022
Acetaminophen injection had annual sales of US $72 million in the United States according to IQVIA data
Kopran acquire assets of Abhinandan Rasayan
By IPP Bureau - October 30, 2022
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
